Temozolomide Sun

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
17-03-2022
Ciri produk Ciri produk (SPC)
17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
02-08-2011

Bahan aktif:

temozolomide

Boleh didapati daripada:

Sun Pharmaceutical Industries Europe B.V.

Kod ATC:

L01AX03

INN (Nama Antarabangsa):

temozolomide

Kumpulan terapeutik:

Antineoplastic agents

Kawasan terapeutik:

Glioma; Glioblastoma

Tanda-tanda terapeutik:

Temozolomide Sun is indicated for the treatment of:adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment;children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.

Ringkasan produk:

Revision: 19

Status kebenaran:

Authorised

Tarikh kebenaran:

2011-07-13

Risalah maklumat

                                48
B. PACKAGE LEAFLET
49
PACKAGE LEAFLET: INFORMATION FOR THE USER
TEMOZOLOMIDE SUN 5 MG HARD CAPSULES
TEMOZOLOMIDE SUN 20 MG HARD CAPSULES
TEMOZOLOMIDE SUN 100 MG HARD CAPSULES
TEMOZOLOMIDE SUN 140 MG HARD CAPSULES
TEMOZOLOMIDE SUN 180 MG HARD CAPSULES
TEMOZOLOMIDE SUN 250 MG HARD CAPSULES
temozolomide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Temozolomide SUN is and what it is used for
2.
What you need to know before you take Temozolomide SUN
3.
How to take Temozolomide SUN
4.
Possible side effects
5.
How to store Temozolomide SUN
6.
Contents of the pack and other information
1.
WHAT TEMOZOLOMIDE SUN IS AND WHAT IT IS USED FOR
Temozolomide SUN contains a medicine called temozolomide. This
medicine is an antitumour agent.
Temozolomide SUN is used for the treatment of specific forms of brain
tumours:
-
in adults with newly-diagnosed glioblastoma multiforme. Temozolomide
SUN is at first used
together with radiotherapy (concomitant phase of treatment) and after
that alone (monotherapy
phase of treatment).
-
in children 3 years and older and adult patients with malignant
glioma, such as glioblastoma
multiforme or anaplastic astrocytoma. Temozolomide SUN is used in
these tumours if they
return or get worse after standard treatment.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE TEMOZOLOMIDE SUN
DO NOT TAKE TEMOZOLOMIDE SUN
-
if you are allergic to temozolomide or any of the other ingredients of
this medicine (listed in
section 6).
-
if you have had an allergic reaction to dacarbazine (
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Temozolomide SUN 5 mg hard capsules
Temozolomide SUN 20 mg hard capsules
Temozolomide SUN 100 mg hard capsules
Temozolomide SUN 140 mg hard capsules
Temozolomide SUN 180 mg hard capsules
Temozolomide SUN 250 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
5 mg hard capsules
Each hard capsule contains 5 mg temozolomide.
Excipient with known effect
Each hard capsule contains 30.97 mg of lactose.
20 mg hard capsules
Each hard capsule contains 20 mg temozolomide.
Excipient with known effect
Each hard capsule contains 18.16 mg of lactose.
100 mg hard capsules
Each hard capsule contains 100 mg temozolomide.
Excipient with known effect
Each hard capsule contains 90.801 mg of lactose.
140 mg hard capsules
Each hard capsule contains 140 mg temozolomide.
Excipient with known effect
Each hard capsule contains 127.121 mg of lactose.
180 mg hard capsules
Each hard capsule contains 180 mg temozolomide.
Excipient with known effect
Each hard capsule contains 163.441 mg of lactose.
250 mg hard capsules
Each hard capsule contains 250 mg temozolomide.
Excipient with known effect
Each hard capsule contains 227.001 mg of lactose.
For the full list of excipients, see section 6.1.
3
3.
PHARMACEUTICAL FORM
5 mg hard capsule (capsule)
Hard gelatin capsules, with white opaque cap and body, imprinted in
green ink. The cap is imprinted
with ‘890’. The body is imprinted with ‘5 mg’ and two stripes.
20 mg hard capsule (capsule)
Hard gelatin capsules, with white opaque cap and body, imprinted in
yellow ink. The cap is imprinted
with ‘891’. The body is imprinted with ’20 mg’ and two
stripes.
100 mg hard capsule (capsule)
Hard gelatin capsules, with white opaque cap and body, imprinted in
pink ink. Thw cap is imprinted
with ‘892’. The body is imprinted with ‘100 mg’ and two
stripes.
140 mg hard capsule (capsule)
Hard gelatin capsules, with white opaque cap and body, imprinted in
blue ink. The cap is imprinted
with ‘929’. The b
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 17-03-2022
Ciri produk Ciri produk Bulgaria 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 02-08-2011
Risalah maklumat Risalah maklumat Sepanyol 17-03-2022
Ciri produk Ciri produk Sepanyol 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 02-08-2011
Risalah maklumat Risalah maklumat Czech 17-03-2022
Ciri produk Ciri produk Czech 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Czech 02-08-2011
Risalah maklumat Risalah maklumat Denmark 17-03-2022
Ciri produk Ciri produk Denmark 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 02-08-2011
Risalah maklumat Risalah maklumat Jerman 17-03-2022
Ciri produk Ciri produk Jerman 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 02-08-2011
Risalah maklumat Risalah maklumat Estonia 17-03-2022
Ciri produk Ciri produk Estonia 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 02-08-2011
Risalah maklumat Risalah maklumat Greek 17-03-2022
Ciri produk Ciri produk Greek 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Greek 02-08-2011
Risalah maklumat Risalah maklumat Perancis 17-03-2022
Ciri produk Ciri produk Perancis 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 02-08-2011
Risalah maklumat Risalah maklumat Itali 17-03-2022
Ciri produk Ciri produk Itali 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Itali 02-08-2011
Risalah maklumat Risalah maklumat Latvia 17-03-2022
Ciri produk Ciri produk Latvia 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 02-08-2011
Risalah maklumat Risalah maklumat Lithuania 17-03-2022
Ciri produk Ciri produk Lithuania 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 02-08-2011
Risalah maklumat Risalah maklumat Hungary 17-03-2022
Ciri produk Ciri produk Hungary 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 02-08-2011
Risalah maklumat Risalah maklumat Malta 17-03-2022
Ciri produk Ciri produk Malta 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Malta 02-08-2011
Risalah maklumat Risalah maklumat Belanda 17-03-2022
Ciri produk Ciri produk Belanda 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 02-08-2011
Risalah maklumat Risalah maklumat Poland 17-03-2022
Ciri produk Ciri produk Poland 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Poland 02-08-2011
Risalah maklumat Risalah maklumat Portugis 17-03-2022
Ciri produk Ciri produk Portugis 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 02-08-2011
Risalah maklumat Risalah maklumat Romania 17-03-2022
Ciri produk Ciri produk Romania 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Romania 02-08-2011
Risalah maklumat Risalah maklumat Slovak 17-03-2022
Ciri produk Ciri produk Slovak 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 02-08-2011
Risalah maklumat Risalah maklumat Slovenia 17-03-2022
Ciri produk Ciri produk Slovenia 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 02-08-2011
Risalah maklumat Risalah maklumat Finland 17-03-2022
Ciri produk Ciri produk Finland 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Finland 02-08-2011
Risalah maklumat Risalah maklumat Sweden 17-03-2022
Ciri produk Ciri produk Sweden 17-03-2022
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 02-08-2011
Risalah maklumat Risalah maklumat Norway 17-03-2022
Ciri produk Ciri produk Norway 17-03-2022
Risalah maklumat Risalah maklumat Iceland 17-03-2022
Ciri produk Ciri produk Iceland 17-03-2022
Risalah maklumat Risalah maklumat Croat 17-03-2022
Ciri produk Ciri produk Croat 17-03-2022

Cari amaran yang berkaitan dengan produk ini